Exhalix, LLC
Corvallis, OR
- UEI
- C1NVZ5M6E319
- CAGE
- 6VB21
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- SAM.gov registration date
- Website
- exhalix-llc.com
- Founded
- 2012
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Hillhurst Biopharmaceuticals, Inc. | Glendale, CA | — |
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Acepre, LLC | Columbia, SC | 325412 Pharmaceutical Preparation Manufacturing |
| Sequitur Health Corp. | Scottsdale, AZ | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Tega Therapeutics Inc. | San Diego, CA | 622110 General Medical and Surgical Hospitals |
About the company
Exhalix, LLC is a for-profit Limited Liability Company registered in SAM.gov since October 2012, located in Albuquerque, New Mexico. The company appears to be focused on developing innovative medical technologies centered around hydrogen sulfide (H2S) delivery and its therapeutic applications, with a specific emphasis on precision medical interventions. While limited background information is available from the provided data, the company demonstrates a sophisticated approach to medical research and technology development through its federally funded grant projects.
Exhalix, LLC has received multiple federal grants from prestigious agencies including the National Center for Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Aging, and National Institute of General Medical Sciences. These grants collectively total approximately $598,492 and focus on developing targeted hydrogen sulfide delivery technologies for various medical applications. Specific research projects include developing the GENIE:S platform for treating peripheral artery disease and chronic limb-threatening ischemia, creating a hydrogen sulfide delivery technology for organ preservation during kidney transplantation, investigating techniques for improving surgical incision healing, and developing advanced wound healing interventions for diabetic patients. The company collaborates with research institutions like the University of New Mexico School of Medicine, demonstrating a strategic approach to translational medical research that aims to address complex medical challenges through precision H2S delivery mechanisms.
Quick answers
Is Exhalix, LLC registered in SAM.gov?
Yes. Exhalix, LLC's SAM.gov registration is active through September 15, 2027.
What is Exhalix, LLC's CAGE code?
Exhalix, LLC's CAGE code is 6VB21, and its Unique Entity ID (UEI) is C1NVZ5M6E319.
What is Exhalix, LLC's most recent federal award?
Exhalix, LLC's most recent federal grant award is Genie:S: on-demand sulfide synthesis and delivery platform technology for ischemia therapy (R43TR005284), from National Center for Advancing Translational Sciences (NIH), on September 16, 2025.
On GovTribe
See Exhalix, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors